Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiSaver in acute myocardial infarction
NCT07134712Phase 2Not yet recruiting
- Sponsor
- HONYA Medical
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Stem Cell Therapies
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of MiSaver in acute myocardial infarction (AMI) (3 arms), sponsored by HONYA Medical. Primary endpoints: Adverse Events at 12 months, Graft-versus-Host Disease at 3 months and 1 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
MiSaver
03
Conditions
acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT07134712.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07134712.